Your browser doesn't support javascript.
The kinetics of viral load and antibodies to SARS-CoV-2.
Sun, Jiufeng; Tang, Xi; Bai, Ru; Liang, Chumin; Zeng, Lilian; Lin, Huifang; Yuan, Runyu; Zhou, Pingping; Huang, Xuhe; Xiong, Qianlin; Peng, Jinju; Cui, Fengfu; Ke, Bixia; Su, Juan; Liu, Zhe; Lu, Jing; Tian, Junzhang; Sun, Ruilin; Ke, Changwen.
  • Sun J; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Tang X; The First Hospital of Foshan, Foshan, China.
  • Bai R; The Guangdong Second Provincial General Hospital, Guangzhou, China.
  • Liang C; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Zeng L; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Lin H; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Yuan R; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Zhou P; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Huang X; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Xiong Q; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Peng J; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Cui F; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Ke B; Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Su J; Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Liu Z; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Lu J; Guangdong Provincial Institute of Public Health, Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China.
  • Tian J; The Guangdong Second Provincial General Hospital, Guangzhou, China.
  • Sun R; The First Hospital of Foshan, Foshan, China. Electronic address: jz.tian@163.com.
  • Ke C; Guangdong Provincial Centre for Disease Control and Prevention, Guangzhou, China. Electronic address: kecw1965@aliyun.com.
Clin Microbiol Infect ; 26(12): 1690.e1-1690.e4, 2020 Dec.
Article in English | MEDLINE | ID: covidwho-1018998
ABSTRACT

OBJECTIVES:

The aim was to understand persistence of the virus in body fluids the and immune response of an infected host to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), an agent of coronavirus disease 2019 (COVID-19).

METHODS:

We determined the kinetics of viral load in several body fluids through real time reverse transcription polymerase chain reaction, serum antibodies of IgA, IgG and IgM by enzyme-linked immunosorbent assay and neutralizing antibodies by microneutralization assay in 35 COVID-19 cases from two hospitals in Guangdong, China.

RESULTS:

We found higher viral loads and prolonged shedding of virus RNA in severe cases of COVID-19 in nasopharyngeal (1.3 × 106 vs 6.4 × 104, p < 0.05; 7∼8 weeks) and throat (6.9 × 106 vs 2.9 × 105, p < 0.05; 4∼5 weeks), but similar in sputum samples (5.5 × 106 vs 0.9 × 106, p < 0.05; 4∼5 weeks). Viraemia was rarely detected (2.8%, n = 1/35). We detected early seroconversion of IgA and IgG at the first week after illness onset (day 5, 5.7%, n = 2/35). Neutralizing antibodies were produced in the second week, and observed in all 35 included cases after the third week illness onset. The levels of neutralizing antibodies correlated with IgG (rs = 0.85, p < 0.05; kappa = 0.85) and IgA (rs = 0.64, p < 0.05; kappa = 0.61) in severe, but not mild cases (IgG, rs = 0.42, kappa = 0.33; IgA, rs = 0.32, kappa = 0.22). No correlation with IgM in either severe (rs = 0.17, kappa = 0.06) or mild cases (rs = 0.27, kappa = 0.15) was found.

DISCUSSION:

We revealed a prolonged shedding of virus RNA in the upper respiratory tract, and evaluated the consistency of production of IgG, IgA, IgM and neutralizing antibodies in COVID-19 cases.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Body Fluids / Virus Shedding / Viral Load / COVID-19 / Antibodies, Viral Type of study: Experimental Studies Limits: Humans Country/Region as subject: Asia Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2020 Document Type: Article Affiliation country: J.cmi.2020.08.043

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Body Fluids / Virus Shedding / Viral Load / COVID-19 / Antibodies, Viral Type of study: Experimental Studies Limits: Humans Country/Region as subject: Asia Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2020 Document Type: Article Affiliation country: J.cmi.2020.08.043